In this article, Scott Mazza of Vitality CBD examines the role of flavonoids in shaping cannabis color, flavor, and aroma, alongside their lesser-known biological functions within the plant. The article explains how flavonoids interact with terpenes and cannabinoids as part of the entourage effect, potentially influencing therapeutic outcomes, particularly in full-spectrum formulations. Mazza also emphasizes the need for deeper research and informed consumer scrutiny, especially regarding product composition, testing standards, and claims around anxiety and other health applications.

In a guest column for NY Cannabis Insider, Scott Mazza explains how the one-year extension of the 2018 Farm Bill delays long-awaited clarity on CBD regulation and hemp-derived cannabinoids, including delta-8 THC, prolonging uncertainty for producers, consumers, and regulators. He outlines how the extension constrains industry planning and innovation while urging producers to rely on third-party testing, transparent labeling, and compliance with existing hemp thresholds to protect consumers during the interim. Mazza argues that clearer federal definitions and enforceable standards in Farm Bill 2024 are essential to stabilize the market, address emerging cannabinoid loopholes, and align regulation with growing scientific evidence and public acceptance.

In a commentary for Nutritional Outlook, Scott Mazza reviews 2023 as a year of regulatory stagnation but meaningful scientific and social progress for CBD, highlighting the delayed Farm Bill update, ongoing uncertainty around delta-8 THC, and FDA hesitation on CBD as a dietary supplement. He outlines key research milestones from the year, including emerging evidence on CBD’s role in opioid use disorder, dosage safety thresholds, hair loss, and other health conditions that continue to reshape the compound’s scientific credibility. Mazza concludes that declining social stigma and growing consumer adoption position CBD for further maturation in 2024, provided policymakers deliver clearer regulatory guidance and enforceable production standards.

In a guest column for NY Cannabis Insider, Scott Mazza analyzes new toxicology research that establishes evidence-based upper limits for daily CBD intake, moving the industry beyond informal dosage “guesstimates.” He highlights findings indicating that healthy adults can safely consume up to 160 mg of CBD per day, while lower limits apply to pregnant or breastfeeding individuals and those at risk of liver injury. Mazza argues that clearly defined dosage thresholds are a necessary step toward responsible regulation, informed consumer use, and the integration of CBD into mainstream health and wellness frameworks.

In a guest column for NY Cannabis Insider, Scott Mazza reviews emerging clinical evidence linking cannabis-based therapies to symptom relief in fibromyalgia, a chronic condition affecting millions of Americans with limited treatment options. He cites recent studies showing that THC- and cannabinoid-containing formulations were associated with statistically significant improvements in pain, depression, and quality of life, as well as reduced reliance on conventional medications. Mazza emphasizes that realizing this therapeutic potential will require more rigorous research alongside stricter industry standards for cannabinoid product purity, potency, and consistency to support medical use.

In an article for Nutritional Outlook, Scott Mazza examines emerging research suggesting that topical hemp formulations rich in cannabinoids, including CBD, may support hair regrowth and could offer an alternative or complement to conventional treatments like finasteride and minoxidil. He highlights findings from a small clinical case series reporting significant hair regrowth without adverse effects, while emphasizing that the mechanism of action appears distinct from existing therapies. Mazza cautions that meaningful progress in CBD-based hair health depends on stronger industry-wide standards for purity, potency, and labeling to ensure consumer safety and scientific credibility.

In an article for Cannabis & Tech Today, Scott Mazza argues that reclassifying cannabis from Schedule I to Schedule III would mark a pivotal shift in U.S. drug policy by reducing stigma, expanding access to scientific research, and aligning federal law with current medical evidence and public opinion. He highlights how rescheduling would ease restrictions on clinical trials, accelerate innovation in areas such as pain management and mental health, and improve access to banking and capital for cannabis businesses. Mazza concludes that grounding cannabis policy in data and science could deliver broad societal, economic, and research benefits while creating a more equitable regulatory environment for the industry.

In this article, Scott Mazza examines delta-8 THC as a hemp-derived cannabinoid operating in a legal gray area shaped by the 2018 Farm Bill, inconsistent state-level restrictions, and limited federal guidance. He explains how delta-8 is typically synthesized from hemp-derived CBD, why its psychoactive effects are often described as milder than delta-9 THC, and how regulatory gaps have contributed to quality, safety, and labeling concerns across the market. Mazza argues that clearer federal legislation and enforceable production standards are necessary to protect consumers, enable legitimate research, and bring regulatory certainty to the delta-8 category.

In this expert commentary for Cannabis Health, Scott Mazza, co-founder and COO of Vitality CBD, examines the growing use of CBD in fitness while cautioning athletes about industry-wide quality and safety risks. He outlines preclinical evidence supporting CBD’s potential role in inflammation reduction, recovery, mobility, and sleep, while emphasizing that poor testing standards and contamination remain significant concerns. The article underscores the need for transparent labeling, third-party testing, organic production, and careful dosing so athletes can use CBD responsibly and minimize avoidable risks.

In this Buffalo Rising guest commentary, Scott Mazza, founder of Vitality CBD, analyzes Buffalo’s path from cannabis legalization to its first recreational dispensary opening, highlighting regulatory delays and the uneven rollout of retail licenses in Western New York. Drawing on his perspective as a license applicant, he details how court challenges, CAURD licensing rules, and state-level pauses have shaped the local market while expanding opportunities remain uncertain. The article situates Buffalo at a pivotal moment, examining the tension between regulated, gray, and unregulated cannabis markets and outlining what these dynamics mean for the city’s economic and cultural future.

In this industry analysis published by Nutritional Outlook, Scott Mazza, co-founder and COO of Vitality CBD, explains why delta-8 THC has become one of the most contested compounds in the hemp market, outlining its chemistry, production from hemp-derived CBD, and reported consumer effects. He examines the regulatory gray area created by the 2018 Farm Bill, contrasting federal legality with increasing state-level restrictions and FDA warnings tied to product safety and unsubstantiated claims. The article argues for clearer legislation, stronger quality standards, and expanded research to resolve uncertainty around delta-8 THC and protect both consumers and the broader hemp industry.

This The Bluntness feature by Scott Mazza, co-founder and COO of Vitality CBD, explores how terpenes shape flavor, effects, and therapeutic outcomes beyond THC alone. Citing peer-reviewed research, Mazza explains how specific terpene–cannabinoid combinations (“chemovars”) are linked to differing levels of symptom relief for conditions such as pain, anxiety, and depression. He argues that moving away from marketing-driven strain names toward chemical profiling is critical for advancing medical credibility, consumer transparency, and evidence-based cannabis use.